can semaglutide cause diabetic retinopathy diabetes - SemaglutideNAION risk worsening of diabetic retinopathy Can Semaglutide Cause Diabetic Retinopathy? Understanding the Ocular Risks

Semaglutidenaion The advent of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has revolutionized the management of diabetes and obesity. While its benefits in improving glycemic control and aiding weight loss are well-documented, questions have emerged regarding its potential impact on eye health, specifically concerning diabetic retinopathy. This article delves into the current understanding of whether semaglutide can indeed cause or worsen diabetic retinopathy, exploring the nuances of this complex relationship, and incorporating information from extensive research.

Diabetic retinopathy is a serious complication of diabetes that affects the blood vessels in the retina. It is a progressive condition that can lead to vision loss and blindness if left untreated. Given that individuals with diabetes are already at an increased risk for ocular complications, any new treatment must be evaluated for its safety profile concerning these existing risksStudy links weight-loss drug to rare eye condition.

The Controversy: Potential for Worsening vs.Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in ... No Increased Risk

The relationship between semaglutide and diabetic retinopathy has been a subject of ongoing research and discussion.Semaglutide and the eye - Oculist Italiano Early clinical trials, such as the SUSTAIN-6 trial, observed a notable 0.8% increase in DR (diabetic retinopathy) with oral semaglutide compared to placebo, even in patients with proliferative DR who were initially excluded from the study. This finding generated concerns that semaglutide could potentially worsen sight-threatening diabetic retinopathy. Further research has indicated that rapid glycemic control, achieved with a sudden drop in A1c levels due to semaglutide treatment, may temporarily worsen diabetic retinopathy due to alterations in retinal blood flow. This phenomenon is thought to stress the delicate blood vessels in the retina, potentially leading to leakage or bleeding.

However, it is crucial to note that a significant body of evidence suggests a more reassuring picture. Many studies and analyses indicate that, in most people taking semaglutide, do not develop diabetic retinopathy or experience a worsening of existing diabetic retinopathy. For instance, real-world evidence from an OHDSI network study does not suggest an increased risk of diabetic retinopathy complications with semaglutide. Another study presented in November 2023 found that semaglutide rarely leads to a worsening of diabetic retinopathy.2024年4月15日—Some studies have shown that Ozempic maycausevision changes or worsen complications ofdiabetic retinopathy. Furthermore, some research, including a systematic review of ocular adverse events, concluded that semaglutide was not associated with an increased risk of eye disorders or diabetic retinopathy. The IRIS Registry-based study similarly found that the majority of patients initiating semaglutide for their type 2 diabetes did not experience a negative impact on their diabetic retinopathy status.

Specific Ocular Considerations and Related Conditions

Beyond diabetic retinopathy, the question of semaglutide's impact on overall eye health necessitates an examination of other potential ocular effects. While some studies have shown that Ozempic (the brand name for semaglutide) may cause vision changes, including blurred vision and macular complications, these are often transient.

A more specific concern that has been investigated is the link between semaglutide and nonarteritic anterior ischemic optic neuropathy (NAION)Semaglutide and Associated Ophthalmic Risks - EyeWiki. NAION is a sudden, painless loss of vision caused by reduced blood flow to the optic nerve. Studies have indicated a potential association, with one analysis finding participants prescribed semaglutide for diabetes to be four times more likely to develop NAION compared to those not on the medication. The "Related searches" for this topic, including "Semaglutide NAION risk" and "The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy," highlight the attention this potential side effect has received. The exact mechanism linking semaglutide and NAION is still being explored, but it is theorized to involve vascular changes.

It is important to differentiate between the potential for semaglutide to *cause* diabetic retinopathy and its potential to *temporarily worsen* it in individuals who already have the condition. The latter is more frequently cited, often linked to rapid improvements in blood sugar.

The Evolving Body of Evidence and Expert Opinions

The scientific community continues to gather and analyze data to provide a clearer picture of semaglutide's ophthalmic safety. Expert opinions vary, reflecting the ongoing nature of this research作者：JT Hathaway·2024·被引用次数：243—Related to vision, patients withdiabetic retinopathywho receivedsemaglutideincurred a higher risk of exacerbation of the retinopathy .... Some ophthalmologists express caution, particularly for patients with pre-existing severe diabetic retinopathy, advising close monitoring of their vision while on semaglutide therapy. This cautious approach is echoed in discussions about "Ozempic use and worsening diabetic retinopathy."

Conversely, many clinicians emphasize that for the vast majority of patients, the benefits of semaglutide in managing diabetes and its associated complications, including a reduced risk of further progression of diabetic retinopathy through improved blood sugar control, outweigh the potential for ocular side effects. A review of the literature by T Rabinovitch highlights that semaglutide can be a game-changer for those with diabetic retinopathy by significantly improving blood sugar control, which in turn reduces the risk of further damage.

Factors to Consider and Future Directions

Several factors can influence the relationship between semaglutide and eye health. These include the individual's baseline diabetic retinopathy status, the duration of diabetes, the degree of glycemic control prior to treatment, and other co-existing health conditions.Ozempic and other weight-loss drugs linked to rare but ... Ultimately, the decision to use semaglutide should be made in consultation with a healthcare provider who can assess individual risks and benefits.Weight Loss Injections; are they safe for your eyes?

Long-term studies, such as the ongoing "Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes" (NCT03811561), are crucial for understanding the sustained impact of these medications. As more data becomes available, our understanding of semaglutide's role in diabetic retinopathy and other ocular conditions will continue to evolve.2025年5月21日—Some clinical studies have found that a small number of people taking Ozempic (semaglutide) experience worsening of theirdiabetic retinopathy.

In conclusion, while some studies have reported an increased incidence of diabetic retinopathy or transient worsening associated with semaglutide, a significant amount of evidence suggests that semaglutide is not definitively linked to *causing* diabetic retinopathy in most individuals. The potential for temporary exacerbation, particularly with rapid blood sugar control, is a recognized phenomenon.Weight Loss Injections; are they safe for your eyes? The emergence of research into semaglutide and NAION warrants further investigation. Open communication between patients and their healthcare providers is paramount to ensure safe and effective management of diabetes and its potential complications.2023年11月3日—A majority of patients did not experience worsening of theirdiabetic retinopathy(DR) after initiatingsemaglutide(Ozempic) to treat their type 2 diabetes (T ...